| General Information | |
|---|---|
| ZINC ID | ZINC000040936433 |
| Molecular Weight (Da) | 490 |
| SMILES | O=C(Cn1nc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2Cl)n1)NCc1ccc(F)cc1 |
| Molecular Formula | C23Cl3F1N4O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 125.146 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| LogP | 6.566 |
| Activity (Ki) in nM | 234.423 |
| Polar Surface Area (PSA) | 59.81 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.11587953 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 23 |
| Fraction csp3 | 0.09 |
| Ilogp | 3.41 |
| Xlogp3 | 6.49 |
| Wlogp | 6.3 |
| Mlogp | 4.09 |
| Silicos-it log p | 6.2 |
| Consensus log p | 5.3 |
| Esol log s | -7.04 |
| Esol solubility (mg/ml) | 0.0000452 |
| Esol solubility (mol/l) | 9.22E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.54 |
| Ali solubility (mg/ml) | 0.0000141 |
| Ali solubility (mol/l) | 2.87E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.36 |
| Silicos-it solubility (mg/ml) | 2.14E-08 |
| Silicos-it solubility (mol/l) | 4.38E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.68 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.32 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.467 |
| Logd | 4.39 |
| Logp | 5.759 |
| F (20%) | 0.001 |
| F (30%) | 0.001 |
| Mdck | - |
| Ppb | 100.63% |
| Vdss | 1.272 |
| Fu | 1.14% |
| Cyp1a2-inh | 0.692 |
| Cyp1a2-sub | 0.158 |
| Cyp2c19-inh | 0.919 |
| Cyp2c19-sub | 0.068 |
| Cl | 10.805 |
| T12 | 0.007 |
| H-ht | 0.246 |
| Dili | 0.982 |
| Roa | 0.074 |
| Fdamdd | 0.504 |
| Skinsen | 0.035 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.011 |
| Bcf | 2.985 |
| Igc50 | 4.887 |
| Lc50 | 6.749 |
| Lc50dm | 5.976 |
| Nr-ar | 0.006 |
| Nr-ar-lbd | 0.018 |
| Nr-ahr | 0.307 |
| Nr-aromatase | 0.264 |
| Nr-er | 0.368 |
| Nr-er-lbd | 0.006 |
| Nr-ppar-gamma | 0.305 |
| Sr-are | 0.838 |
| Sr-atad5 | 0.031 |
| Sr-hse | 0.009 |
| Sr-mmp | 0.658 |
| Sr-p53 | 0.361 |
| Vol | 444.979 |
| Dense | 1.097 |
| Flex | 0.292 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.36 |
| Synth | 2.313 |
| Fsp3 | 0.087 |
| Mce-18 | 23 |
| Natural product-likeness | -1.576 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |